查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1956792

血友病基因治疗市场分析及预测（至2035年）：依类型、产品类型、技术、应用、最终使用者、流程、功能、安装类型及解决方案划分

Hemophilia Gene Therapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Functionality, Installation Type, Solutions
出版日期: | 出版商: Global Insight Services | 英文 302 Pages | 商品交期: 3-5个工作天内

价格
简介目录

血友病基因治疗市场预计将从2024年的5亿美元成长到2034年的27.1亿美元，复合年增长率约为18.7%。血友病基因治疗市场涵盖了直接针对血友病遗传病因的创新治疗方法，有望提供长期解决方案。这些治疗方法旨在恢復缺失凝血因子的生成，从而减少或消除出血发作。随着研究的深入，由于盛行率的上升、研发投入的增加以及监管部门的核准，该市场蓄势待发，即将迎来成长。市场关注的重点是提高疗效、安全性和可及性，并为个人化医疗以及生物技术公司与医疗服务提供者之间的合作提供了巨大的机会。

受基因工程技术的进步和血友病患者数量的增加的推动，血友病基因治疗市场预计将呈现强劲增长。其中，A型血友病基因治疗领域成长最为显着，主要得益于载体技术的重大进步及令人鼓舞的临床试验结果。 BB型血友病基因治疗紧随其后，递送机制的创新提高了治疗效果。腺结合病毒（AAV）载体因其已证实的安全性和基因转移效率而脱颖而出。慢病毒载体由于能够整合到宿主基因组中并提供长期表达，正迅速成为第二大成长领域。生物技术公司之间的策略联盟和合作进一步巩固了市场，推动了创新并加速了研发进程。 CRISPR等新型基因编辑技术的出现为血友病治疗提供了盈利的机会，有望带来更精准、更持久的治疗效果。

市场区隔
类型 A型血友病A，B型血友病
产品 基因治疗载体、重组蛋白
科技 腺结合病毒（AAV）载体、慢病毒载体、逆转录病毒载体
目的 临床试验、研究与开发以及商业用途
最终用户 医院、专科诊所、研究机构、生物製药公司
流程 体内基因治疗，体外基因治疗
功能 基因转移，基因编辑
安装类型 独立式、整合式
解决方案 治疗方案、诊断方案

血友病基因治疗市场正蓬勃发展，各大区域的市占率分布不均。定价策略也不断调整，以满足日益增长的创新治疗方法需求。在基因工程和个人化医疗技术的推动下，新产品上市速度加快。各公司正致力于建立策略联盟，以增强产品系列併扩大市场覆盖范围。市场格局的特点是拥有丰富的创新治疗方法有望彻底改变治疗模式。血友病基因治疗市场的竞争日益激烈，新参与企业不断涌现，现有企业之间也出现了整合。监管机构的影响力至关重要，其严格的指导方针规范着市场准入和产品核可流程。对竞争对手的比较分析表明，各公司都非常重视临床疗效和安全性。在有利的报销政策和患者意识不断提高的推动下，市场蓄势待发，预计将实现成长。为了增强竞争优势并掌握新的机会，各公司纷纷透过策略联盟和併购来巩固自身地位。

主要趋势和驱动因素：

受基因研究进展和创新治疗方法的推动，血友病基因治疗市场正经历变革性成长。关键趋势包括聚焦个人化医疗，从而实现量身定制的治疗方案，改善患者预后并减少副作用。尖端CRISPR技术的整合正在革新基因编辑领域，提供更精准有效的治疗选择。此外，监管机构认识到基因治疗在满足未被满足的医疗需求方面的潜力，正在加快基因治疗的核准流程，为研发投资创造有利环境。血友病患病率的不断上升以及医疗保健支出的成长，进一步推动了市场扩张。新兴市场蕴藏着许多机会，这些市场的医疗基础设施正在发展，人们对基因治疗的认知也不断提高。能够成功应对监管环境并证明其长期疗效和安全性的公司有望占据显着的市场份额。凭藉持续的技术创新和策略合作，血友病基因治疗市场预计将保持持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • A型血友病A
    • B型血友病
  • 市场规模及预测：依产品划分
    • 基因治疗载体
    • 重组蛋白
  • 市场规模及预测：依技术划分
    • 腺结合病毒（AAV）载体
    • 慢病毒载体
    • 逆转录病毒载体
  • 市场规模及预测：依应用领域划分
    • 临床试验
    • 研究与开发
    • 商业用途
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 研究机构
    • 生物製药公司
  • 市场规模及预测：依製程划分
    • 体内基因治疗
    • 体外基因治疗
  • 市场规模及预测：依功能划分
    • 基因替代疗法
    • 基因编辑
  • 市场规模及预测：依安装类型划分
    • 独奏
    • 一体化
  • 市场规模及预测：按解决方案划分
    • 治疗方案
    • 诊断解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • uni Qure
  • Bio Marin Pharmaceutical
  • Sangamo Therapeutics
  • Spark Therapeutics
  • Freeline Therapeutics
  • Hemab Therapeutics
  • Dimension Therapeutics
  • REGENXBIO
  • Intellia Therapeutics
  • Editas Medicine
  • CRISPR Therapeutics
  • Thermo Fisher Scientific
  • Voyager Therapeutics
  • Audentes Therapeutics
  • Bluebird Bio
  • Precision Bio Sciences
  • Poseida Therapeutics
  • Generation Bio
  • Logic Bio Therapeutics
  • Beam Therapeutics

第九章：关于我们

简介目录
Product Code: GIS32340

Hemophilia Gene Therapy Market is anticipated to expand from $500.0 million in 2024 to $2.71 billion by 2034, growing at a CAGR of approximately 18.7%. The Hemophilia Gene Therapy Market encompasses innovative treatments that address the genetic root of hemophilia, offering potential long-term solutions. These therapies aim to restore deficient clotting factor production, reducing or eliminating bleeding episodes. As research advances, the market is poised for growth, driven by increasing prevalence, rising R&D investments, and regulatory approvals. The focus is on improving efficacy, safety, and accessibility, with significant opportunities in personalized medicine and partnerships between biotech firms and healthcare providers.

The Hemophilia Gene Therapy Market is poised for robust growth, fueled by advancements in genetic engineering and increasing prevalence of hemophilia. The segment of hemophilia A gene therapies is the top performer, driven by significant advancements in vector technology and promising clinical trial outcomes. Hemophilia B gene therapies follow closely, with innovations in delivery mechanisms enhancing therapeutic efficacy. The adeno-associated virus (AAV) vector sub-segment stands out, benefiting from its proven safety profile and efficiency in gene transfer. Lentiviral vectors are gaining momentum as the second highest performing sub-segment, due to their ability to integrate into the host genome and provide long-term expression. The market is further bolstered by strategic partnerships and collaborations among biotech firms, fostering innovation and accelerating development timelines. The emergence of novel gene-editing technologies, such as CRISPR, presents lucrative opportunities, offering potential for more precise and durable therapeutic outcomes in hemophilia treatment.

Market Segmentation
TypeHemophilia A, Hemophilia B
ProductGene Therapy Vectors, Recombinant Proteins
TechnologyAdeno-Associated Virus (AAV) Vector, Lentivirus Vector, Retrovirus Vector
ApplicationClinical Trials, Research and Development, Commercial Use
End UserHospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
ProcessIn Vivo Gene Therapy, Ex Vivo Gene Therapy
FunctionalityGene Addition, Gene Editing
Installation TypeStandalone, Integrated
SolutionsTherapeutic Solutions, Diagnostic Solutions

The Hemophilia Gene Therapy Market is witnessing a dynamic evolution with varied market share distribution across key regions. Pricing strategies are adapting to accommodate the increasing demand for innovative therapies. New product launches are accelerating, driven by advancements in genetic engineering and personalized medicine. Companies are focusing on strategic collaborations to enhance their product portfolios and expand their reach. The market landscape is characterized by a robust pipeline of novel therapies, promising to revolutionize treatment paradigms. Competition in the Hemophilia Gene Therapy Market is intensifying with the entry of new players and the consolidation of existing ones. Regulatory influences play a pivotal role, with stringent guidelines shaping market entry and product approval processes. Benchmarking against competitors reveals a focus on clinical efficacy and safety profiles. The market is poised for growth, supported by favorable reimbursement policies and increasing patient awareness. Strategic alliances and mergers are prevalent, as companies aim to bolster their competitive edge and capitalize on emerging opportunities.

Geographical Overview:

The Hemophilia Gene Therapy Market is witnessing substantial growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and significant investments in gene therapy research. The presence of key industry players and supportive regulatory frameworks further bolster market expansion in this region. Europe follows closely, with a strong focus on innovative healthcare solutions and increasing funding for genetic research. The region's commitment to improving patient outcomes through cutting-edge therapies enhances its market position. In the Asia Pacific, the market is rapidly expanding due to rising healthcare expenditure and growing awareness about gene therapies. Emerging economies, such as China and India, are investing heavily in biotechnology and healthcare advancements. Latin America and the Middle East & Africa represent promising growth pockets. In Latin America, improving healthcare infrastructure and rising demand for advanced treatments are driving market growth. Meanwhile, the Middle East & Africa are increasingly recognizing the potential of gene therapies to address unmet medical needs, fostering market development.

Global tariffs and geopolitical tensions are increasingly influencing the Hemophilia Gene Therapy Market. Japan and South Korea are navigating these complexities by enhancing domestic R&D capabilities and seeking strategic partnerships to mitigate reliance on foreign technologies. China, amid export controls, is accelerating its gene therapy innovation, focusing on self-sufficiency and regulatory advancements. Taiwan, while pivotal in biopharmaceutical production, faces geopolitical vulnerabilities that could disrupt supply chains. The global market shows robust growth, driven by advancements in gene therapy and increasing prevalence of hemophilia. By 2035, the market is anticipated to flourish, contingent on stable geopolitical landscapes and resilient supply chains. Middle East conflicts could indirectly affect this market by influencing energy prices, impacting operational costs and logistical frameworks.

Key Trends and Drivers:

The hemophilia gene therapy market is experiencing transformative growth, driven by advancements in genetic research and innovative treatment methodologies. A key trend is the increasing focus on personalized medicine, allowing for tailored therapies that improve patient outcomes and reduce adverse effects. The integration of cutting-edge CRISPR technology is revolutionizing gene editing, offering more precise and efficient treatment options. Moreover, regulatory bodies are accelerating the approval processes for gene therapies, recognizing their potential to address unmet medical needs. This is fostering a favorable environment for research and development investments. The growing prevalence of hemophilia, coupled with rising healthcare expenditure, is further propelling market expansion. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness about gene therapies is increasing. Companies that can navigate regulatory landscapes and demonstrate long-term efficacy and safety are poised to capture significant market share. With ongoing technological advancements and strategic partnerships, the hemophilia gene therapy market is set to witness sustained growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hemophilia A
    • 4.1.2 Hemophilia B
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Gene Therapy Vectors
    • 4.2.2 Recombinant Proteins
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Adeno-Associated Virus (AAV) Vector
    • 4.3.2 Lentivirus Vector
    • 4.3.3 Retrovirus Vector
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Clinical Trials
    • 4.4.2 Research and Development
    • 4.4.3 Commercial Use
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo Gene Therapy
    • 4.6.2 Ex Vivo Gene Therapy
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Gene Addition
    • 4.7.2 Gene Editing
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 Standalone
    • 4.8.2 Integrated
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Functionality
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Functionality
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Functionality
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Functionality
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Functionality
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Functionality
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Functionality
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Functionality
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Functionality
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Functionality
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Functionality
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Functionality
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Functionality
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Functionality
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Functionality
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Functionality
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Functionality
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Functionality
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Functionality
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Functionality
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Functionality
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Functionality
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Functionality
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Functionality
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 uni Qure
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bio Marin Pharmaceutical
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sangamo Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Spark Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Freeline Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Hemab Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Dimension Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 REGENXBIO
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Intellia Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Editas Medicine
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 CRISPR Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Thermo Fisher Scientific
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Voyager Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Audentes Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bluebird Bio
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Precision Bio Sciences
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Poseida Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Generation Bio
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Logic Bio Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Beam Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us